• SHS Capital signed a binding agreement to acquire a majority stake in Dutch pharmaceutical developer and CDMO Basic Pharma.
• The deal is expected to close shortly; founder and CEO Bob Kool will reinvest alongside SHS Capital.
• Basic Pharma develops and manufactures nasal sprays and semi-solid pharmaceuticals, pairing proprietary dossiers with a “license & supply” model.
• SHS Capital plans to back international expansion, continued product development, operational improvements, and selective acquisitions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SHS Gesellschaft fuer Beteiligungsmanagement mbH published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.